Back to all Thought Leadership

#6: Expedited Programs for Serious Conditions – Drugs and Biologics

December 8, 2016

In May 2014, the FDA published a guidance document entitled “Expedited Programs for Serious Conditions – Drugs and Biologics.”  The intention of the document was to provide drug makers with an incentive to develop products that fill unmet medical needs for serious conditions.  Since its publication, the program established by the guidance document has become an increasingly popular pathway for many companies developing new drug products.

To learn more about this guidance document and its contents, view our previous blog post on the topic, entitled “Taking the Mystery Out Of Expedited Approvals.”

Do you think your product may fall into the category of drugs covered by this incentive program?  Are you seeking expedited approval for an applicable drug product?  We can help you achieve a successful interaction with FDA.  To learn more about our services and capabilities, contact us today.

If you have any questions or thoughts on this blog post or others, please contact us today.
General Regulatory Regulatory Sciences



Related Articles

Medical Information Drug Supply Chain Security Act A person scanning a prescription medication into the computer

August 15, 2023

What is the Drug Supply Chain Security Act (DSCSA)?

Update: The FDA has recently granted a one-year extension until November 27, 2024, for the enforcement of system-wide electronic interoperable systems that track products throughout the supply chain....

Read the Full Article
Agency Alerts General Regulatory

June 14, 2016

FDA Clarifies Regulations Regarding How Patients May Be Charged for Investigational Drugs

On Thursday, June 2nd the FDA issued a final guidance, entitled “Charging for Investigational Drugs Under an IND — Questions and Answers.” The guidance provides information concerning the...

Read the Full Article
Agency Alerts General Regulatory

June 5, 2017

US Opioid Epidemic: NDA for Drug to Treat Opioid Use Disorder Submitted to FDA

On Tuesday, May 30th, Indivior Plc., a British company focused on addiction treatment, submitted a New Drug Application (NDA) to the FDA for its investigational drug intended to treat...

Read the Full Article